Literature DB >> 17318547

Does combined imaging of the pre- and postsynaptic dopaminergic system increase the diagnostic accuracy in the differential diagnosis of parkinsonism?

Walter Koch1, Christine Hamann, Perry E Radau, Klaus Tatsch.   

Abstract

PURPOSE: We hypothesized that combining pre- and postsynaptic quantitative information about the dopaminergic system would provide a higher diagnostic accuracy in the differential diagnosis of parkinsonism than specific striatal D(2) receptor binding alone. Therefore, the aim of the study was to introduce new semi-quantitative parameters and evaluate their ability to discriminate between Parkinson's disease (IPS) and non-idiopathic parkinsonian syndromes (non-IPS).
METHODS: In 100 patients (69 IPS, 31 non-IPS), postsynaptic [(123)I]IBZM and presynaptic [(123)I]FP-CIT SPECT scans were evaluated by observer-independent techniques. The diagnostic performances of striatal dopamine transporter (DAT) and D(2) receptor binding, their respective asymmetries, and a combination of pre- and postsynaptic asymmetry were evaluated with ROC analyses. A logistic regression model was generated combining factors to calculate the probability for each patient of belonging to either diagnostic group.
RESULTS: D(2) receptor binding provided a sensitivity of 87.1% and a specificity of 72.5% with an area under the curve (AUC) of 0.866. The AUCs of other single parameters were lower than that of D(2) binding. A gain of diagnostic power (p = 0.026) was reached with a model combining pre- and postsynaptic asymmetries and D(2) binding (sensitivity 90.3%, specificity 73.9%, AUC 0.893).
CONCLUSION: The combination of quantitative parameters of presynaptic DAT and postsynaptic D(2) receptor binding demonstrates superior diagnostic power in the differentiation of patients with IPS and non-IPS than the established approach based on D(2) binding alone. Striatal D(2) receptor binding and the combination of DAT and IBZM binding asymmetries are the factors contributing most in separating these diagnostic groups.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17318547     DOI: 10.1007/s00259-007-0375-8

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   10.057


  44 in total

1.  Optimization of automated quantification of 123I-IBZM uptake in the striatum applied to parkinsonism.

Authors:  P E Radau; R Linke; P J Slomka; K Tatsch
Journal:  J Nucl Med       Date:  2000-02       Impact factor: 10.057

2.  European Association of Nuclear Medicine procedure guidelines for brain neurotransmission SPET using (123)I-labelled dopamine D(2) transporter ligands.

Authors:  K Tatsch; S Asenbaum; P Bartenstein; A Catafau; C Halldin; L S Pilowsky; A Pupi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-10       Impact factor: 9.236

3.  [3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy.

Authors:  B Bokobza; M Ruberg; B Scatton; F Javoy-Agid; Y Agid
Journal:  Eur J Pharmacol       Date:  1984-03-23       Impact factor: 4.432

4.  The evolution of diagnosis in early Parkinson disease. Parkinson Study Group.

Authors:  J Jankovic; A H Rajput; M P McDermott; D P Perl
Journal:  Arch Neurol       Date:  2000-03

5.  Drug-naive patients with Parkinson's disease in Hoehn and Yahr stages I and II show a bilateral decrease in striatal dopamine transporters as revealed by [123I]beta-CIT SPECT.

Authors:  G Tissingh; P Bergmans; J Booij; A Winogrodzka; E A van Royen; J C Stoof; E C Wolters
Journal:  J Neurol       Date:  1998-01       Impact factor: 4.849

6.  [Clinical impact of cerebral dopamine-D2 receptor scintigraphy].

Authors:  R Larisch; A Klimke
Journal:  Nuklearmedizin       Date:  1998       Impact factor: 1.379

7.  Accuracy of clinical diagnosis in parkinsonism--a prospective study.

Authors:  A H Rajput; B Rozdilsky; A Rajput
Journal:  Can J Neurol Sci       Date:  1991-08       Impact factor: 2.104

8.  Age-related changes in D2 receptor binding with iodine-123-iodobenzofuran SPECT.

Authors:  M Ichise; J R Ballinger; F Tanaka; M Moscovitch; P H St George-Hyslop; D Raphael; M Freedman
Journal:  J Nucl Med       Date:  1998-09       Impact factor: 10.057

Review 9.  PET studies on the early and differential diagnosis of Parkinson's disease.

Authors:  D J Brooks
Journal:  Neurology       Date:  1993-12       Impact factor: 9.910

10.  Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease.

Authors:  G Tissingh; J Booij; P Bergmans; A Winogrodzka; A G Janssen; E A van Royen; J C Stoof; E C Wolters
Journal:  J Nucl Med       Date:  1998-07       Impact factor: 10.057

View more
  18 in total

Review 1.  SPECT imaging evaluation in movement disorders: far beyond visual assessment.

Authors:  Kosmas Badiavas; Elisavet Molyvda; Ioannis Iakovou; Magdalini Tsolaki; Kyriakos Psarrakos; Nikolaos Karatzas
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-12-02       Impact factor: 9.236

2.  Tumoural denervation of the nigrostriatal pathway.

Authors:  Martin Victor Añaños; Teresa Baringo; Paola Lievano; Leticia De la Cueva; Pablo Navarro; Estela Arroyo; Mario Gonzalez; Dolores Abos
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-09-24       Impact factor: 9.236

3.  Pre- and postsynaptic dopamine SPECT in the early phase of idiopathic parkinsonism: a population-based study.

Authors:  Susanna Jakobson Mo; Jan Linder; Lars Forsgren; Anne Larsson; Lennart Johansson; Katrine Riklund
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-07-01       Impact factor: 9.236

Review 4.  The role of functional dopamine-transporter SPECT imaging in parkinsonian syndromes, part 2.

Authors:  T C Booth; M Nathan; A D Waldman; A-M Quigley; A H Schapira; J Buscombe
Journal:  AJNR Am J Neuroradiol       Date:  2014-06-12       Impact factor: 3.825

5.  The cost effectiveness of 123I-FP-CIT SPECT imaging in patients with an uncertain clinical diagnosis of parkinsonism.

Authors:  Koen Van Laere; Ludwig Everaert; Lieven Annemans; Michel Gonce; Wim Vandenberghe; Thierry Vander Borght
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-04-02       Impact factor: 9.236

6.  Is absolute quantification of dopaminergic neurotransmission studies with 123I SPECT ready for clinical use?

Authors:  Habib Zaidi; Georges El Fakhri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-07       Impact factor: 9.236

Review 7.  New Imaging Markers for Movement Disorders.

Authors:  Christine Ghadery; Antonio P Strafella
Journal:  Curr Neurol Neurosci Rep       Date:  2018-04-03       Impact factor: 5.081

Review 8.  [Differential diagnostics of Parkinson's disease with nuclear medicine procedures].

Authors:  P T Meyer; F Amtage; S Hellwig
Journal:  Nervenarzt       Date:  2014-06       Impact factor: 1.214

Review 9.  Neuroimaging in Parkinson disease: from research setting to clinical practice.

Authors:  Marios Politis
Journal:  Nat Rev Neurol       Date:  2014-11-11       Impact factor: 42.937

10.  Clinical neuroimaging: a matter of biophysics and logistics.

Authors:  Giovanni Lucignani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-06       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.